The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro

Detalhes bibliográficos
Autor(a) principal: Eberle, Raphael J.
Data de Publicação: 2021
Outros Autores: Olivier, Danilo S., Amaral, Marcos S., Gering, Ian, Willbold, Dieter, Arni, Raghuvir K. [UNESP], Coronado, Monika A. [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3390/v13050873
http://hdl.handle.net/11449/206432
Resumo: Since the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CLpro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CLpro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CLpro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment.
id UNSP_d317a8ecdd612ba20cb2cb122b48e4b5
oai_identifier_str oai:repositorio.unesp.br:11449/206432
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro3CLproCOVID-19Main proteaseQuinacrineRepurposing approved drugsSARS-CoV-2SuraminSince the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CLpro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CLpro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CLpro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment.Universidade Federal de Mato Grosso do SulFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do SulConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Institute of Biological Information Processing (IBI-7 Structural Biochemistry) Forschungszentrum JülichInstitut für Physikalische Biologie Heinrich-Heine-Universität Düsseldorf, UniversitätsstraßeCampus Cimba Federal University of TocantinsInstitute of Physics Federal University of Mato Grosso do SulJuStruct: Jülich Centre for Structural Biology Forchungszentrum JülichMultiuser Center for Biomolecular Innovation IBILCE Universidade Estadual Paulista (UNESP)Multiuser Center for Biomolecular Innovation IBILCE Universidade Estadual Paulista (UNESP)FAPESP: 2016/12904-0FAPESP: 2018/07572-3FAPESP: 2018/12659-0FAPESP: 2019/05614-3Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul: 23/200.307/2014CNPq: 307338/2014-2CNPq: 401270/2014-9CNPq: 435913/2016-6Forschungszentrum JülichHeinrich-Heine-Universität DüsseldorfFederal University of TocantinsFederal University of Mato Grosso do SulForchungszentrum JülichUniversidade Estadual Paulista (Unesp)Eberle, Raphael J.Olivier, Danilo S.Amaral, Marcos S.Gering, IanWillbold, DieterArni, Raghuvir K. [UNESP]Coronado, Monika A. [UNESP]2021-06-25T10:31:58Z2021-06-25T10:31:58Z2021-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/v13050873Viruses, v. 13, n. 5, 2021.1999-4915http://hdl.handle.net/11449/20643210.3390/v130508732-s2.0-85107200195Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengVirusesinfo:eu-repo/semantics/openAccess2021-10-23T04:34:36Zoai:repositorio.unesp.br:11449/206432Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T18:20:35.354916Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
title The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
spellingShingle The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
Eberle, Raphael J.
3CLpro
COVID-19
Main protease
Quinacrine
Repurposing approved drugs
SARS-CoV-2
Suramin
title_short The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
title_full The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
title_fullStr The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
title_full_unstemmed The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
title_sort The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
author Eberle, Raphael J.
author_facet Eberle, Raphael J.
Olivier, Danilo S.
Amaral, Marcos S.
Gering, Ian
Willbold, Dieter
Arni, Raghuvir K. [UNESP]
Coronado, Monika A. [UNESP]
author_role author
author2 Olivier, Danilo S.
Amaral, Marcos S.
Gering, Ian
Willbold, Dieter
Arni, Raghuvir K. [UNESP]
Coronado, Monika A. [UNESP]
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Forschungszentrum Jülich
Heinrich-Heine-Universität Düsseldorf
Federal University of Tocantins
Federal University of Mato Grosso do Sul
Forchungszentrum Jülich
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Eberle, Raphael J.
Olivier, Danilo S.
Amaral, Marcos S.
Gering, Ian
Willbold, Dieter
Arni, Raghuvir K. [UNESP]
Coronado, Monika A. [UNESP]
dc.subject.por.fl_str_mv 3CLpro
COVID-19
Main protease
Quinacrine
Repurposing approved drugs
SARS-CoV-2
Suramin
topic 3CLpro
COVID-19
Main protease
Quinacrine
Repurposing approved drugs
SARS-CoV-2
Suramin
description Since the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CLpro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CLpro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CLpro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-25T10:31:58Z
2021-06-25T10:31:58Z
2021-01-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3390/v13050873
Viruses, v. 13, n. 5, 2021.
1999-4915
http://hdl.handle.net/11449/206432
10.3390/v13050873
2-s2.0-85107200195
url http://dx.doi.org/10.3390/v13050873
http://hdl.handle.net/11449/206432
identifier_str_mv Viruses, v. 13, n. 5, 2021.
1999-4915
10.3390/v13050873
2-s2.0-85107200195
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Viruses
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128921921650688